Emmanuel S Antonarakis
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Antonarakis E, Procopio G, Fukasawa S, Tabata K, Park S, Feyerabend S, Drake C, Wu H, Qiu P, Kim J, Poehlein C, Omlin A, Li C, Piulats J, Gross-Goupil M, Goh J, Ojamaa K, Hoimes C, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, de Bono J. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol 2019:JCO1901638.
Nov 27, 2019Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Nov 27, 2019J Clin Oncol 2019:JCO1901638
Antonarakis Emmanuel S, Procopio Giuseppe, Fukasawa Satoshi, Tabata Ken-Ichi, Park Se Hoon, Feyerabend Susan, Drake Charles G, Wu Haiyan, Qiu Ping, Kim Jeri, Poehlein Christian, Omlin Aurelius, Li Chunde, Piulats Josep M, Gross-Goupil Marine, Goh Jeffrey, Ojamaa Kristiina, Hoimes Christopher J, Vaishampayan Ulka, Berger Ranaan, Sezer Ahmet, Alanko Tuomo, de Wit Ronald, de Bono Johann Sebastian
Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy
VanderWeele D, Sweeney C, Petrylak D, Morgans A, Higano C, Gillessen Sommer S, Fizazi K, Dreicer R, Carducci M, Antonarakis E, Hussain M. Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. J Clin Oncol 2019; 37:2961-2967.
Sep 10, 2019Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy
Sep 10, 2019J Clin Oncol 2019; 37:2961-2967
VanderWeele David J, Sweeney Christopher J, Petrylak Daniel P, Morgans Alicia K, Higano Celeste S, Gillessen Sommer Silke, Fizazi Karim, Dreicer Robert, Carducci Michael A, Antonarakis Emmanuel S, Hussain Maha